Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the NFATc1, c-Fos, and MAPK pathways

키워드

참고문헌 (43)

1. Novack DV, "The osteoclast : friend or foe?", Annu Rev Pathol, 3, pp.457~484 (2008)
2. Nakashima T, "Evidence for osteocyte regulation of bone homeostasis through RANKL expression", Nat Med, 17, pp.1231~1234 (2011)
3. Rodan GA, "Therapeutic approaches to bone diseases", Science, 289, pp.1508~1514 (2000)
4. Rivollier A, "Immature dendritic cell transdifferentiation into osteoclasts : a novel pathway sustained by the rheumatoid arthritis microenvironment", Blood, 104, pp.4029~4037 (2004)
5. Roodman GD, "Cell biology of the osteoclast", Exp Hematol, 27, pp.1229~1241 (1999)
6. Takeshita S, "SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts", Nat Med, 8, pp.943~949 (2002)
7. Genant HK, "Estrogens in the prevention of osteoporosis in postmenopausal women", Am J Obstet Gynecol, 161, pp.1842~1846 (1989)
8. Reid IR, "Pharmacotherapy of osteoporosis in postmenopausal women : focus on safety", Expert Opin Drug Saf, 1, pp.93~107 (2002)
9. Kong YY, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", Nature, 397, pp.315~323 (1999)
10. Lee ZH, "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochem Biophys Res Commun, 305, pp.211~214 (2003)
11. Lee SE, "The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation", Bone, 30, pp.71~77 (2002)
12. Li J, "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism", Proc Natl Acad Sci U S A, 97, pp.1566~1571 (2000)
13. Walsh MC, "Osteoimmunology : interplay between the immune system and bone metabolism", Annu Rev Immunol, 24, pp.33~63 (2006)
14. Chang Y, "Ginsenosides Rg1 and Rb1 enhance glutamate release through activation of protein kinase A in rat cerebrocortical nerve terminals(synaptosomes)", Eur J Pharmacol, 578, pp.28~36 (2008)
15. Chen WF, "Activation of insulin-like growth factor I receptormediated pathway by ginsenoside Rg1", Br J Pharmacol, 147, pp.542~551 (2006)
16. Lau WS, "Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERalpha pathway", J Steroid Biochem Mol Biol, 108, pp.64~71 (2008)
17. Pan XY, "Ginsenoside Rg3attenuates cell migration via inhibition of aquaporin 1expression in PC-3M prostate cancer cells", Eur J Pharmacol, 683, pp.27~34 (2012)
18. Kim HR, "Effect of ginseng mixture on osteoporosis in ovariectomized rats", Immunopharmacol Immunotoxicol, 30, pp.333~345 (2008)
19. Liu J, "20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity", Bioorg Med Chem Lett, 19, pp.3320~3323 (2009)
20. Yuan HD, "Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3beta via AMP-activated protein kinase to inhibit hepatic glucose production in HepG2 cells", Chem Biol Interact, 195, pp.35~42 (2012)
21. Zhang G, "Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia", J Ethnopharmacol, 115, pp.441~448 (2008)
22. Qianqian Xue, "Protective effect and mechanism of ginsenoside Rg2 on atherosclerosis", Journal of Ginseng Research, 47(2), pp.237~245 (2023), 고려인삼학회
23. Zhou L, "SIRT5 promotes IDH2desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense", EMBO Rep, 17, pp.811~822 (2016)
24. Yao F, "Phenolic compounds and ginsenosides in ginseng shoots and their antioxidant and anti-inflammatory capacities in LPS-induced RAW264. 7 mouse macrophages", Int J Mol Sci, 20, pp.2951~ (2019)
25. Wang ZQ, "Bone and haematopoietic defects in mice lacking c-fos", Nature, 360, pp.741~745 (1992)
26. Takayanagi H, "Induction and activation of the transcription factor NFATc1(NFAT2)integrate RANKL signaling in terminal differentiation of osteoclasts", Dev Cell, 3, pp.889~901 (2002)
27. Lee JH, "Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal", Mol Pharmacol, 77, pp.17~25 (2010)
28. Nedeva IR, "Role of OSCAR signaling in osteoclastogenesis and bone disease", Front Cell Dev Biol, 9, pp.641162~ (2021)
29. Kim HN, "Anti-inflammatory effect of Vaccinium oldhamii stems through inhibition of NF-kappaB and MAPK", ATF2 signaling activation in LPSstimulated RAW264. 7 cells, 2019, pp.19, 291~
30. Teitelbaum SL, "Genetic regulation of osteoclast development and function", Nat Rev Genet, 4, pp.638~649 (2003)
31. Teitelbaum SL, "RANKing c-Jun in osteoclast development", J Clin Invest, 114, pp.463~465 (2004)
32. Kiefer D, "Panax ginseng", Am Fam Physician, 68, pp.1539~1542 (2003)
33. Grigoriadis AE, "c-Fos : a key regulator of osteoclast-macrophage lineage determination and bone remodeling", Science, 266, pp.443~448 (1994)
34. Yamashita T, "NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand(RANKL)and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1", J Biol Chem, 282, pp.18245~18253 (2007)
35. Wagner EF, "Fos", AP-1 proteins in bone and the immune system, 2005, pp.208, 126~140
36. Gohda J, "RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis", EMBO J, 24, pp.790~799 (2005)
37. Takayanagi H, "Osteoimmunology : shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)
38. Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
39. Ang E, "Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-kappaB and ERK", J Cell Biochem, 112, pp.89~97 (2011)
40. Kim HJ, "Suppression of osteoclastogenesis by N, N-dimethyl-D-erythro-sphingosine : a sphingosine kinase inhibition-independent action", Mol Pharmacol, 72, pp.418~428 (2007)
41. Monje P, "Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1", J Biol Chem, 280, pp.35081~35084 (2005)
42. Ikeda F, "Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation", J Clin Invest, 114, pp.475~484 (2004)
43. Matsumoto M, "Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand(RANKL)", J Biol Chem, 275, pp.31155~31161 (2000)

관련 논문AI추천